| Literature DB >> 35986260 |
Ya Su1,2, Michiko Yuki3, Natsuka Ogawa4.
Abstract
BACKGROUND: Screening and intervention in pre-frailty can help prevent or delay frailty among older adults. Being overweight has shown associated with pre-frailty, and overweight is highly prevalent among community-dwelling older adults during COVID-19. However, the impact of visceral fat accumulation remains unclear. This study aimed to explore the association between visceral fat area and pre-frailty in community-dwelling older adults.Entities:
Keywords: COVID-19; Older adults; Pre-frailty; Visceral fat area
Mesh:
Year: 2022 PMID: 35986260 PMCID: PMC9388358 DOI: 10.1186/s12877-022-03377-w
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 4.070
Association of overweight and impact of the COVID-19 pandemic with pre-frailty
| Variables | Total | Robust | Pre-frail | Effect size ( | 95% C.I | |
|---|---|---|---|---|---|---|
| Age | 75.4 ± 5.4 | 74.7 ± 6.0 | 75.7 ± 5.1 | 0.316 | 0.187 | -0.136–0.511 |
| Sex (women) | 138 (69.7) | 36 (73.5) | 102 (68.5) | 0.508 | ||
| SMM (kg) | 21.03 ± 6.34 | 20.30 ± 3.73 | 21.28 ± 4.09 | 0.178 | 0.245 | -0.079–0.568 |
| SMI (kg/m2) | 6.34 ± 0.87 | 6.15 ± 0.83 | 6.40 ± 0.88 | 0.087 | 0.288 | -0.036–0.612 |
| BMR (kcal) | 1214.94 ± 143.45 | 1186.92 ± 132.11 | 1224.15 ± 146.23 | 0.159 | 0.260 | -0.063–0.584 |
| PBF (%) | 30.2 ± 7.1 | 28.5 ± 7.5 | 30.8 ± 6.9 | 0.057 | 0.326 | 0.002–0.651 |
| BMI (kg/m2) | 23.5 ± 3.3 | 22.4 ± 3.1 | 23.8 ± 3.2 | 0.009* | 0.441 | 0.115–0.767 |
| VFA (cm2) | 81.5 ± 32.8 | 71.6 ± 28.9 | 84.8 ± 33.5 | 0.015* | 0.407 | 0.082–0.732 |
| a Overweight (%BF) | 127 (64.1) | 30 (61.2) | 97 (65.1) | 0.624 | 0.070 | -0.209–0.349 |
| b Overweight (BMI) | 62 (33.6) | 12 (24.5) | 50 (33.6) | 0.235 | 0.164 | -0.110–0.449 |
| c Overweight (VFA) | 54 (27.3) | 7 (14.3) | 47 (31.5) | 0.019* | 0.338 | 0.056–0.621 |
| The number of prescription medications taken per day | 2 (0–13) | 1 (0–6) | 2 (0–13) | 0.011* | 0.368 | 0.084–0.651 |
| Depression (GDS5 ≥ 2) | 68 (34.3) | 11 (22.4) | 57 (38.3) | 0.043* | 0.291 | 0.009–0.572 |
| Cannot sleep well | 17 (8.6) | 4 (8.2) | 13 (8.7) | 0.903 | 0.017 | -0.261–0.296 |
| Stress and anxiety | 50 (25.3) | 8 (16.3) | 42 (28.2) | 0.097 | 0.238 | -0.043–0.518 |
| Going out less than last year | 154 (77.8) | 31 (63.3) | 122 (82.6) | 0.005* | 0.407 | 0.123–0.691 |
Results are presented as mean ± SD, median (range), or n (%)
Abbreviations: SMM Skeletal Muscle Mass, SMI Skeletal Muscle mass Index, BMR Basal Metabolic Rate, PBF Percentage of body fat, BMI Body Mass Index, VFA Visceral fat area, CI Confidence interval
a Overweight: Men: PBF ≥ 25%, Women: PBF ≥ 30%
b Overweight, BMI ≥ 25 kg/m2
c Overweight: Visceral fat area ≥ 100 cm2
* P-value < 0. 05
Association of visceral fat area with frailty indicators
| Variables | Total | Visceral fat area | ||
|---|---|---|---|---|
| < 100 cm2 | ≥ 100 cm2
| |||
| Age | 75.4 ± 5.4 | 75.7 ± 5.6 | 74.8 ± 4.6 | 0.318 |
| Sex (women) | 138 (69.7) | 96 (66.7) | 42 (77.8) | 0.130 |
| Weight loss | 30 (15.2) | 24 (16.7) | 6 (11.1) | 0.332 |
| Low physical function | 114 (57.6) | 75 (52.1) | 39 (72.2) | 0.011* |
| Low physical activity | 169 (85.4) | 126 (87.5) | 43 (79.6) | 0.163 |
| Memory loss | 8 (4.0) | 6 (4.2) | 2 (3.7) | 1.000 |
| Exhaustion | 21 (10.6) | 12 (8.3) | 9 (16.7) | 0.090 |
| 149 (75.3) | 102 (70.8) | 47 (87.0) | 0.019* | |
Results are presented as mean ± SD, or n (%)
* P-value < 0. 05
Fig. 1The distribution of BMI and VAF by sex. The following four groups were divided according to BMI and VFA: Non-BMI overweight and non-high VAF; BMI overweight and non-high VAF; BMI overweight and high VAF; non-BMI overweight but have high VAF
Association of visceral fat area with Pre-frailty in logistic regression analysis
| Variables | Crude | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|
| Crude OR (95% CI) | Adjusted OR (95% CI) | |||
| Age | 1.02 (0.96 − 1.09) | 1.04 (0.97 − 1.03) | 1.01 (0.94 − 1.08) | 1.02 (0.95 − 1.09) |
| Sex (women) | 0.84 (0.41 − 1.74) | 0.76 (0.36 − 1.61) | 0.72 (0.33 − 1.54) | 0.58 (0.26 − 1.31) |
| VFA ≥ 100 cm2 | ||||
| The number of prescription medications taken per day | ||||
| Depression | ||||
| Going out less than last year due to the COVID-19 | ||||
Abbreviations: OR Odds ratio, CI Confidence interval, VFA Visceral fat area
Model 1: Adjusted for sex and age. Goodness-of-fit: H‐L Chi2 (8) = 6.8716, p = 0.568
Model 2: Adjusted for sex, age, the number of prescription medications taken per day, and depression. Goodness-of-fit: H‐L Chi2 (8) = 1.128, p = 0.997
Model 3: Adjusted for sex, age, the number of prescription medications taken per day, depression, and going out less than last year due to the COVID-19. Goodness-of-fit: H‐L Chi2 (8) = 6.449, p = 0.597